Target Name: IL10RA
NCBI ID: G3587
Review Report on IL10RA Target / Biomarker Content of Review Report on IL10RA Target / Biomarker
IL10RA
Other Name(s): IL-10R subunit alpha | interleukin 10 receptor, alpha | Interleukin-10 receptor alpha chain | I10R1_HUMAN | Interleukin-10 receptor subunit 1 | Interleukin 10 receptor subunit alpha, transcript variant 1 | interleukin-10 receptor subunit 1 | Interleukin-10 receptor subunit alpha | IL-10R subunit 1 | IL-10 receptor subunit alpha | IL-10R1 | CD210a | Interleukin 10 receptor, alpha | interleukin-10 receptor alpha chain | interleukin 10 receptor subunit alpha | IL10RA variant 1 | CDw210a | HIL-10R | CD210 | CDW210A | IL10R | IL-10RA

IL-10R as A Potential Drug Target for Cancer and Autoimmune Disorders

The Interleukin-10 (IL-10) signaling pathway is a crucial regulator of immune and inflammatory responses.IL-10R, a subunit of the IL-10 receptor, has been identified as a potential drug target for the treatment of various diseases, including cancer, autoimmune disorders, and chronic obstructive pulmonary disease (COPD).

IL-10 is a cytokine that plays a central role in the regulation of immune responses and inflammation. It is produced by various immune cells, including T cells, B cells, and macrophages, and promotes the activation and proliferation of these cells. High levels of IL-10 have been associated with the development and progression of many diseases, including cancer, autoimmune disorders, and COPD.

The IL-10 signaling pathway involves the interactions of multiple proteins, including IL-10R, which is a key regulator of the pathway. IL-10R is a transmembrane protein that is expressed in various tissues and cells, including the lungs, spleen, and peripheral blood cells. It consists of two distinct subunits, IL-10R1 and IL-10R2, which are responsible for different aspects of the signaling pathway.

The IL-10R signaling pathway is involved in the regulation of immune responses, inflammation, and fibrosis. It is known to be involved in the regulation of T cell proliferation and differentiation, as well as the regulation of immune cell function. High levels of IL-10R have been observed in various diseases, including cancer, autoimmune disorders, and COPD, and have been associated with the development and progression of these conditions.

One of the potential benefits of targeting IL-10R is its potential as a drug target. By inhibiting the activity of IL-10R, it is possible to reduce the production of IL-10 and the inflammation that it promotes. This can have a therapeutic impact on a variety of diseases, including cancer, autoimmune disorders, and COPD.

In cancer, IL-10R has been shown to be involved in the regulation of cancer cell growth and survival. High levels of IL-10R have been observed in various types of cancer, including breast, lung, and ovarian cancer. studies have shown that inhibiting the activity of IL-10R can be an effective way to treat cancer, particularly in cases where traditional therapies have become ineffective.

In autoimmune disorders, IL-10R is involved in the regulation of the immune response. It has been shown to play a role in the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. By inhibiting the activity of IL-10R, it may be possible to reduce the inflammation and improve the symptoms of these disorders.

In addition to its role in cancer and autoimmune disorders, IL-10R is also involved in the regulation of fibrosis. Fibrosis is a complex process that involves the excessive growth and scarring of tissues, and is associated with a variety of diseases, including cancer, chronic obstructive pulmonary disease (COPD), and skin diseases. IL-10R has been shown to be involved in the regulation of fibrosis, and inhibiting its activity may be an effective way to treat these conditions.

In conclusion, IL-10R is a protein that plays a central role in the regulation of immune and inflammatory responses. It is a potential drug target for the treatment of various diseases, including cancer, autoimmune disorders, and COPD. By inhibiting its activity, it may be possible to reduce inflammation and improve the symptoms of these conditions. Further research is needed to fully understand the role of IL-10R in the regulation of immune and inflammatory responses and to develop effective treatments.

Protein Name: Interleukin 10 Receptor Subunit Alpha

Functions: Cell surface receptor for the cytokine IL10 that participates in IL10-mediated anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Upon binding to IL10, induces a conformational change in IL10RB, allowing IL10RB to bind IL10 as well (PubMed:16982608). In turn, the heterotetrameric assembly complex, composed of two subunits of IL10RA and IL10RB, activates the kinases JAK1 and TYK2 that are constitutively associated with IL10RA and IL10RB respectively (PubMed:12133952). These kinases then phosphorylate specific tyrosine residues in the intracellular domain in IL10RA leading to the recruitment and subsequent phosphorylation of STAT3. Once phosphorylated, STAT3 homodimerizes, translocates to the nucleus and activates the expression of anti-inflammatory genes. In addition, IL10RA-mediated activation of STAT3 inhibits starvation-induced autophagy (PubMed:26962683)

The "IL10RA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL10RA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL10RB | IL10RB-DT | IL11 | IL11RA | IL12A | IL12A-AS1 | IL12B | IL12RB1 | IL12RB2 | IL13 | IL13RA1 | IL13RA2 | IL15 | IL15RA | IL16 | IL17A | IL17B | IL17C | IL17D | IL17F | IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP